High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.


Journal

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436

Informations de publication

Date de publication:
02 2023
Historique:
received: 09 03 2022
accepted: 07 11 2022
medline: 28 3 2023
pubmed: 5 2 2023
entrez: 4 2 2023
Statut: ppublish

Résumé

The information on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in patients with IBD and healthy controls (HCs). Patients with IBD and HCs (contact of patients) underwent SARS-CoV-2 antibody testing (chemiluminescent immunoassay: Siemens kit IgG against antigen-S1RBD) between July 2020 and April 2021. Information on demography, disease characteristics, drug history and past history of SARS-CoV-2 infection were noted. Patients on 5-aminosalicylic acid or no treatment were considered not on immunosuppressants and those who had received steroids, thiopurines or methotrexate within six months of inclusion were considered being on immunosuppressants. A total of 235 patients (51.9%, males; mean age, 38.7 ± 12.4 years; median disease duration, 60 months [interquartile range, IQR: 36-120]) (ulcerative colitis [UC]: 69.4%, Crohn's disease [CD]: 28.9%, IBD unclassified [IBDU]: 1.7%) and 73 HCs (mean age, 39.6 ± 10.9 years, 80% males) were enrolled. Of the 235 patients, 128 (54.5%) patients were on immunosuppressants and 107 (45.5%) were not on immunosuppressants. Seventy-four (31.5%) patients were seropositive, of which two (0.9%) had previous history of SARS-CoV-2 infection and none received coronavirus disease-19 (COVID-19) vaccine. Seroprevalence between IBD patients and HCs (32% vs. 27%, p > 0.05) and between patients with and without immunosuppressants (28.1% vs. 36%, p > 0.05) was similar. Age, gender, disease type, duration and activity in the last six months; and medication use were similar between patients with positive and negative serology. There was a progressive increase in seroprevalence from July 2020 to April 2021. Up to 1/3rd of patients with IBD were seropositive for immunoglobulin G (IgG) SARS-Cov-2 antibody indicating high seroprevalence in patients with IBD from Northern India.

Sections du résumé

BACKGROUND
The information on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in patients with IBD and healthy controls (HCs).
METHODS
Patients with IBD and HCs (contact of patients) underwent SARS-CoV-2 antibody testing (chemiluminescent immunoassay: Siemens kit IgG against antigen-S1RBD) between July 2020 and April 2021. Information on demography, disease characteristics, drug history and past history of SARS-CoV-2 infection were noted. Patients on 5-aminosalicylic acid or no treatment were considered not on immunosuppressants and those who had received steroids, thiopurines or methotrexate within six months of inclusion were considered being on immunosuppressants.
RESULTS
A total of 235 patients (51.9%, males; mean age, 38.7 ± 12.4 years; median disease duration, 60 months [interquartile range, IQR: 36-120]) (ulcerative colitis [UC]: 69.4%, Crohn's disease [CD]: 28.9%, IBD unclassified [IBDU]: 1.7%) and 73 HCs (mean age, 39.6 ± 10.9 years, 80% males) were enrolled. Of the 235 patients, 128 (54.5%) patients were on immunosuppressants and 107 (45.5%) were not on immunosuppressants. Seventy-four (31.5%) patients were seropositive, of which two (0.9%) had previous history of SARS-CoV-2 infection and none received coronavirus disease-19 (COVID-19) vaccine. Seroprevalence between IBD patients and HCs (32% vs. 27%, p > 0.05) and between patients with and without immunosuppressants (28.1% vs. 36%, p > 0.05) was similar. Age, gender, disease type, duration and activity in the last six months; and medication use were similar between patients with positive and negative serology. There was a progressive increase in seroprevalence from July 2020 to April 2021.
CONCLUSION
Up to 1/3rd of patients with IBD were seropositive for immunoglobulin G (IgG) SARS-Cov-2 antibody indicating high seroprevalence in patients with IBD from Northern India.

Identifiants

pubmed: 36738383
doi: 10.1007/s12664-022-01310-y
pii: 10.1007/s12664-022-01310-y
pmc: PMC9898695
doi:

Substances chimiques

Immunosuppressive Agents 0
Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-78

Subventions

Organisme : All-India Institute of Medical Sciences
ID : A-COVID34

Informations de copyright

© 2023. Indian Society of Gastroenterology.

Références

Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.
doi: 10.1038/s41586-020-2008-3 pubmed: 32015508 pmcid: 7094943
Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017;15:138–41.
doi: 10.5217/ir.2017.15.1.138 pubmed: 28239326 pmcid: 5323305
Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the great shift east. Inflamm Intest Dis. 2017;2:102–15.
doi: 10.1159/000465522 pubmed: 30018961 pmcid: 5988149
Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134–47.
doi: 10.1111/j.1751-2980.2010.00429.x pubmed: 20579217
Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879–913.
doi: 10.1093/ecco-jcc/jjab052 pubmed: 33730753
Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159:6-13.e6.
doi: 10.1053/j.gastro.2020.04.002 pubmed: 32272113
Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020;53:98-105.e5.
doi: 10.1016/j.immuni.2020.06.001 pubmed: 32561270 pmcid: 7276322
Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8.
doi: 10.1038/s41591-020-0897-1 pubmed: 32350462
Caini S, Bellerba F, Corso F, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill. 2020;25:2000980.
doi: 10.2807/1560-7917.ES.2020.25.23.2000980 pubmed: 32553061 pmcid: 7403641
Berte’ R, Mazza S, Stefanucci MR, et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy. J Crohns Colitis. 2021;15:864–8.
doi: 10.1093/ecco-jcc/jjaa237 pubmed: 33211810
Freeman MC, Rapsinski GJ, Zilla ML, Wheeler SE. Immunocompromised seroprevalence and course of illness of SARS-CoV-2 in one pediatric quaternary care center. A J Pediatric Infect Dis Soc. 2021;10:426–31.
doi: 10.1093/jpids/piaa123 pubmed: 33049042
Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11:3774.
Norsa L, Cosimo P, Indriolo A, Sansotta N, D’Antiga L, Callegaro A. Asymptomatic severe acute respiratory syndrome coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology. 2020;159:2229-31.e2.
Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70:865–75.
doi: 10.1136/gutjnl-2021-324388 pubmed: 33753421
Scucchi L, Neri B, Sarmati L, et al. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2021;25:2418–24.
pubmed: 33755981
McGregor CG, Adams A, Sadler R, et al. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Gut. 2021;70:2398–400.
doi: 10.1136/gutjnl-2021-324116 pubmed: 33579788
Łodyga M, Maciejewska K, Eder P, et al. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pol Arch Intern Med. 2021;131:226–32.
pubmed: 33544564
Bossa F, Carparelli S, Latiano A, et al. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021;53:277–82.
doi: 10.1016/j.dld.2020.12.120 pubmed: 33423942 pmcid: 7834247
Dailey J, Kozhaya L, Dogan M, et al. Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2022;28:1019–26.
doi: 10.1093/ibd/izab207 pubmed: 34528661
Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients. J Crohns Colitis. 2022;16:389–97.
doi: 10.1093/ecco-jcc/jjab153 pubmed: 34473254
Di Ruscio M, Lunardi G, Buonfrate D, et al. A seroprevalence study of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease during the second wave of the COVID-19 pandemic in Italy. Medicina (Kaunas). 2021;57:1048.
doi: 10.3390/medicina57101048 pubmed: 34684085
Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications.  J Crohns Colitis. 2019;13:144–64.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A.
doi: 10.1155/2005/269076 pubmed: 16151544
Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.
doi: 10.1136/gut.43.1.29 pubmed: 9771402 pmcid: 1727189
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.
doi: 10.1016/S0016-5085(76)80163-1 pubmed: 1248701
Murhekar MV, Bhatnagar T, Selvaraju S, et al. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152:48–60.
doi: 10.4103/ijmr.IJMR_3290_20 pubmed: 32952144 pmcid: 7853249
Murhekar MV, Bhatnagar T, Selvaraju S, et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021;9:e257–66.
doi: 10.1016/S2214-109X(20)30544-1 pubmed: 33515512 pmcid: 7906675
Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. Int J Infect Dis. 2021;108:145–55.
doi: 10.1016/j.ijid.2021.05.040 pubmed: 34022338 pmcid: 8132496
Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: a population-based cross-sectional study. PLoS Med. 2021;18: e1003877.
doi: 10.1371/journal.pmed.1003877 pubmed: 34890407 pmcid: 8726494
Jahan N, Brahma A, Kumar MS, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis. Int J Infect Dis. 2021;116:59–67.
doi: 10.1016/j.ijid.2021.12.353 pubmed: 34968773 pmcid: 8712428
National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390–400.
doi: 10.1016/S1473-3099(20)30634-4

Auteurs

Bhaskar Kante (B)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Sudheer Kumar Vuyyuru (SK)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Ritu Gupta (R)

Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Tanima Dwivedi (T)

Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Peeyush Kumar (P)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Sandeep Mundhra (S)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Rithvik Golla (R)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Shubi Virmani (S)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Mahak Verma (M)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Govind Makharia (G)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Vineet Ahuja (V)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India.

Saurabh Kedia (S)

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110 029, India. dr.saurabhkedia@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH